Processed and formatted by SEC Watch - Visit SECWatch.

com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 02/24/2009

Myriad Genetics, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-26642

Delaware 87-0494517
(State or other jurisdiction of (IRS Employer
incorporation) Identification No.)

320 Wakara Way

Salt Lake City, Utah 84108
(Address of principal executive offices, including zip code)

801-584-3600
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On February 24, 2009, Myriad Genetics, Inc. announced that its Board of Directors has approved a two-for-one split of the Company's
common stock, effected in the form of a stock dividend. The stock dividend is payable on March 25, 2009 to shareholders of record at the close
of business on March 9, 2009. The information in the press release dated February 24, 2009 is incorporated herein by reference and attached to
this Current Report on Form 8-K as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits

(d)

Exhibit

Number Description

99.1 The Registrant's press release dated February 24, 2009 concerning a two-for-one stock split in the form of a dividend.
 Processed and formatted by SEC Watch - Visit SECWatch.com

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Myriad Genetics, Inc.

Date: February 24, 2009 By: /s/ Peter D. Meldrum

Peter D. Meldrum
President and Chief Executive Officer
 Processed and formatted by SEC Watch - Visit SECWatch.com

Exhibit Index

Exhibit No. Description

EX-99.1 The Registrant's press release dated February 24, 2009 concerning a two-for-one stock split in the form of a dividend.

Contact:

Suzanne Barton

Director, Investor Relations

(801) 584-1138

Email: sbarton@myriad.com

www.myriad.com

FOR IMMEDIATE RELEASE 2/24/09, 4:00 PM EST

Myriad Genetics Announces 2-for-1 Stock Split

Salt Lake City, February 24, 2009 -- Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that its Board of
Directors has approved a two-for-one split of the Company's common stock, effected in the form of a stock dividend.

The stock dividend is payable on March 25, 2009 to shareholders of record at the close of business on March 9, 2009.
Shareholders will receive one additional share for every outstanding share held. As a result of the stock split, the total number
of outstanding shares will increase to approximately 95,000,000.

"We are encouraged with the growing number of healthcare professionals that are recognizing the value of our personalized
medical information - both before and after a patient is diagnosed with cancer," said Peter D. Meldrum, President and Chief
Executive Officer of Myriad Genetics, Inc. "This action also underscores our commitment to provide additional marketability
and liquidity for the company's shares, which may serve to broaden the Company's shareholder base."

Effect of Stock Split on the Proposed Spin-Off of Myriad Pharmaceuticals

As previously announced, Myriad Genetics intends to spin off its research and drug development businesses during the second
calendar quarter of 2009. As initially proposed, for each share of Myriad Genetics' stock, shareholders will receive an
additional one half share in Myriad Pharmaceuticals in the form of a dividend. Giving effect to the two-for-one stock split, it is
anticipated that Myriad Genetics shareholders will now receive one quarter share of Myriad Pharmaceuticals for each share of
Myriad Genetics owned. It is still anticipated that the stock distribution will be tax free to shareholders.

About Myriad Genetics

Myriad Genetics, Inc. is a leading healthcare company focused on the development and marketing of novel
molecular diagnostic and therapeutic products. Myriad's news and other information are available on the
Company's Web site at www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, Azixa and Vivecon
are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries.
MYGN-G

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements relating to the two-for-one stock split in the form of a stock dividend payable on March 25, 2009 to shareholders of record at the close of
 Processed and formatted by SEC Watch - Visit SECWatch.com
business on March 9, 2009; the receipt by the Company's shareholders of one additional share for every outstanding share; the number of
outstanding shares increasing to 95,000,000 as a result of the stock split; the effect of the stock split to provide additional marketability and liquidity
for the Company's shares and to broaden the Company's shareholder base; the Company's intent to spin off its research and drug development
businesses during the second calendar quarter of 2009; the receipt of the Company's shareholders of one quarter share of Myriad Pharmaceuticals for
each owned share of Myriad Genetics; and the anticipation that the stock distribution wil l be tax free to the shareholders. These forward looking
statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk that we may be unable to further identify, develop and achieve commercial success for new products and
technologies; the risk that we may be unable to discover drugs that are safer and more efficacious than our competitors; the risk that we may be unable
to develop manufacturing capability for approved products; the risk that sales of our existing molecular diagnostic products may decline or not
continue to increase at historical rates; the risk that we may be unable to develop additional molecular diagnostic products that help assess which
patients are subject to greater risk of developing diseases and who would therefor e benefit from new preventive therapies; the possibility of delays in
the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result
in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or
that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and
acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we may be unable to protect
our proprietary technologies; the risk of patent-infringement claims; risks of new, changing and competitive technologies and regulations in the
United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form
10-K for the year ended June 30, 2008, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk
factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of
the date of the release, and Myriad undertakes no duty to update this information unless required by law.